

0001628280-25-0039266-K ORGANIGRAM HOLDINGS INC. 2025020520250205072451072454072454 0 0001628280-25-003926 6-K 2 20250205 20250205 20250205 ORGANIGRAM HOLDINGS INC. 0001620737 2834 000000000 Z4 0930 6-K 34 001-38885 25590896 35A ENGLISH DR. MONCTON A3 E1E 3X3 506-384-1571 35A ENGLISH DR. MONCTON A3 E1E 3X3 ORGANIGRAM HOLDINGS INC 20140926 6-K 1 form6-kxfebruary42025.htm 6-K DocumentUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934For the month of February 2025Commission File Number: 001-38885ORGANIGRAM HOLDINGS INC. (Translation of registrant's name into English)145 King Street West, Suite 1400Toronto, Ontario ,Canada M5H 1J8 (Address of principal executive offices)Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ ☒ Form 40-F ☐ ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ ☒ SUBMITTED HEREWITHExhibits99.1 News Release dated February 4, 2025SIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.ORGANIGRAM HOLDINGS INC./s/ Greg Guyatt Greg GuyattChief Financial OfficerDate: February 4, 2025 EX-99.1 2 q1f25noticeofcall-february.htm EX-99.1 DocumentOrganigram to Report First Quarter Fiscal 2025 Results on February 11, 2025Â Â TORONTO--(BUSINESS WIRE)â€œFebruary 4, 2025 -Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the â€œCompanyâ€ or â€œOrganigramâ€), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open.Â The Company will host a conference call to discuss its results with details as follows:Â Â Date: Tuesday, February 11, 2025 Time: 8:00 am Eastern TimeÂ Â To register for the conference call, please use this link:Â <https://registrations.events/direct/Q4I967665>Â To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.Â Â To access the webcast:Â <https://events.q4inc.com/attendee/638837238>Participants will receive their details via email.Â Â A replay of the webcast will be available within 24 hours after the conclusion of the call at <https://www.organigram.ca/investors> and will be archived for a period of 90 days following the call.Â Â About Organigram Holdings Inc.Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include Organigram Inc., a licensed cultivator or cannabis and manufacturer of cannabis-derived goods in Canada, and recently acquired Motif Labs Ltd., a licensed cannabis processor.Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands, including Edison, Big Bag Oâ€™ Buds, SHRED, Monjour and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-SupÃ©rieur, QuÃ©bec, with a dedicated manufacturing facility in Winnipeg, Manitoba. As a result of the acquisition of Motif Labs Ltd. on December 6, 2024, the Company now operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as â€œplansâ€, â€œexpectsâ€, â€œestimatesâ€, â€œintendsâ€, â€œanticipatesâ€, â€œbelievesâ€, â€œcouldâ€, â€œmayâ€, â€œmightâ€ or â€œwillâ€ be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.For Media enquiries: Megan McCrae, Senior Vice President â€œ Global Brands and Corporate Affairsmegan.mccrae@organigram.ca For Investor Relations enquiries: Max Schwartz, Director of Investor Relations investors@organigram.ca